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Introduction
The many and varied theories of the pathogenesis of Meniere's disease are
reflected in the considerable number of drugs which have been used for its
treatment Very few of them have any solid basis of evidence of clinical efficacy—
as indeed is true of many of the surgical procedures which have been devised
(Jongkees, 1980). Among the few which have been subjected to controlled
clinical trials are hydrochlorothiazide (Klockhoff and Lindblom, 1967) and
betahistine hydrochloride (Wilmot and Menon, 1976; Frew and Menon, 1976).
Based on the hypothesis that one of the contributory factors to Meniere's
disease may be an oversecretion of endolymph it was decided to investigate the
effect of O-(B-hydroxyethyl)-rutosides (HR§) in a double-blind cross-over
clinical trial. HR has been shown experimentally to inhibit microvascular
permeability (Arturson, 1972; Hilton, 1980), probably via a 'tightening' of
interendothelial cell junctions (Hammerson, 1970; Arturson 1972; Hladovec
and Rossman, 1973; Prerovsky and Hladovec, 1979). These effects have also
been confirmed in man, both in peripheral tissues (Roztocil et al, 1971, 1977)
and in retinal capillaries (Tschopp et al, 1970). In addition, HR has been shown
to improve capillary perfusion (McEwan and McArdle, 1971) possibly due to an
effect on red cell aggregation and deformability (Van Haeringen et al, 1973;
Schmid-Schonbein, 1975).
Material and Methods —tinnitus (usually of low tone);
Patients —rotatory vertigo.
A * * i n n *• * n n c /- A 1 r, These findings were confirmed by the
A total of 39 patients (29 from Graz and 10
 f o l l o w i n g audiometric assessment:
from Omagh) entered the trial and all
patients fully completed the investigation. P u r e t o n e a/c a n d h'c audiometry, tuning
The basic inclusion criteria were a clinical f o r k tes ts> s P e e c h audiometry and Bekesy
history of at least six months of recurrent audiometry, and the recruitment test,
episodes of: and by the following vestibular function
—peripheral fluctuating recruiting tests:
cochlear (sensori-neural) hearing-loss gaze nystagmus, positional nystagmus
in one or both ears; and caloric tests, in which the speed of the
* University Ear, Nose and Throat Clinic, Graz, Austria.
t Ear, Nose and Throat Department, Tyrone County Hospital, Omagh, Northern Ireland.
X Medical Department, Zyma Pharmaceutical Co., Nyon, Switzerland.
§ Venoruton®/Paroven®—Zyma, Nyon, Switzerland.
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slow component for 10 seconds, starting
10 seconds after cessation of stimulus
for 40 seconds (Omagh centre), or the
number of beats during this same 10-
second period (Graz centre), were
recorded.
In addition, it was required to demonstrate
intact tympanic membranes, positive
Rinne's responses, and a negative
treponemal serology. Only patients who
demonstrated a clear willingness and ability
to co-operate fully in the study, after a full
explanation, were recruited.
Exclusion criteria were pregnancy,
middle-ear disease, defective conductive
hearing-loss and eustachian tube
dysfunction, malignancy, organic disease of
the central nervous system, essential
hypertension, diabetes mellitus, coronary
artery disease, hepatic and renal disorders,
and abuse of alcohol. Regular use of psycho-
tropic drugs such as antidepressants, major
tranquillisers, etc. was also excluded, but
patients receiving minor tranquillisers, and
in whom it was not practicable to stop this
therapy, were allowed to continue on a fixed
dosage.
The characteristics of the patients are
shown in Table I, which shows that the great
majority of patients had unilateral disease,
with considerable variation in the length of
history, as well as in the frequency and
duration of attacks. In general, the 29
patients from Graz had a longer history
(median: five years) than in Omagh (median:
TABLE I
PATIENT CHARACTERISTICS
Number of patients
Sex
Age(mean±SD)
Site of disease
Length of history
(median)
No. of attacks in
preceeding six
months (median)
Average duration of
attacks (median)
Sequence
39
M/24 F/15
48.3 years±11.5 (range
22-68 years)
35 unilateral (R18/L: 17)
four bilateral
Five years (range one to
30 years)
Six (range one to 60)
Two hours (range
20 minutes to 12 hours)
HR/ placebo = 19;
placebo/HR = 20
two years), and also a greater frequency of
attacks (median: 10) than in Omagh
(median: four).
From Table II, which shows the initial
severity of symptoms, it can be seen that all
patients did fulfill the basic triad of inclusion
criteria: vertigo, deafness, and tinnitus. The
majority of patients also complained of
nausea and vomiting with the attacks, and of
a 'fullness of the ear*, but relatively few
presented with headaches.
Trial design
The trial was prospective, double-blind,
cross-over, placebo-controlled, with an
initial 'run-in' period of one month when all
the patients received a placebo, followed by
two consecutive periods each of three
TABLE II
INITIAL SEVERITY OF SYMPTOMS
Rotatory vertigo (n = 39)
Nausea (during attacks)
(n = 39)
Vomiting (during attacks)
(n = 39)
Deafness (n = 43 ears)
Tinnitus (n = 43 ears)
Fullness in ear(n = 43 ears)
Headache (n = 39)
Absent
0
2
9
0
2
'bilateral'
patients
11
26
Mild
4
8
4
35
22
27
10
Severe
17
16
16
18
17
5
3
Very severe
18
13
10
0
2
0
0
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Summary of trial design:
267
Placebo
one month
I
I HR
or placebo .
three months
Placebo
HR
three months
- 1 1
Symptomatic
assessment
Audiometric
assessment
+caloric test
months, when they received HR followed by
placebo or vice versa. The assignment to one
or the other sequence was randomized.
HR was dispensed as tablets of 500 mg. in
the Graz centre (two tablets twice daily) and
as capsules of 250 mg (four capsules twice
daily) in the Omagh centre, because of local
regulatory restrictions. The dissolution times
of these two dosage forms were demon-
strated to be equivalent Total daily dosage
in all patients was therefore 2 g./day. The
placebos were identical in appearance to the
corresponding dose form—tablet or capsule.
The capsules or tablets were dispensed in
bottles containing treatment for a period of
one month.
The main purposes of the run-in period
were:
(a) as a wash-out for any previous drug
therapy;
(b) to enable the patients to familiarise
themselves with the trial procedures;
(c) to obtain some data on the degree of
'stability' and severity of the patients'
symptomatology.
Frequency of examinations
The patients were examined each month
during the total trial duration of seven
months, and the severity of symptoms and
occurrence of any side-effects were
recorded. At each monthly visit, the previous
bottle of tablets was returned, the number of
remaining tablets counted, and a new bottle
issued. In addition, the audiometric assess-
ments and the caloric tests were undertaken
at the beginning and end of the placebo run-in
period, at the time of cross-over, and at the
end of the second treatment period.
Results
Symptoms
Table III shows the overall results for all
symptoms in those patients who showed any
particular symptom at the beginning of the
trial—i.e. beginning of the run-in period.
The most striking finding was that the
majority of patients showed a clear improve-
ment in symptoms (particularly vertigo,
nausea, and vomiting) during this initial
placebo period. Indeed, a considerable
number of patients became free from some
symptoms and remained so for the remainder
of the trial. We therefore excluded these
patients from our subsequent statistical
analyses for those particular symptoms.
Nevertheless, on this basis, no significant
differences appeared on comparing the
severity of each symptom of each patient
during the HR sequence with the severity
during the placebo period.
However, on assessing the data, it became
clear that the improvements on placebo were
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TABLE m
SYMPTOMS; ONLY THOSE PATIENTS SHOWING THE SYMPTOMS ON ENTRY TO THE TRIAL
No. who
improved in
placebo
'run-in'
No. who were then
symptom free during
all subsequent six
months
HR sequence
superior to
placebo sequence
Two
sequences
equal
Placebo
sequence
superior to HR
sequence
Vertigo (n = 39)
Nausea (n = 37)
Vomiting (n = 30)
Tinnitus (n = 39)
Deafness (n = 39)
Fullness in ear (n = 30)
Headache (n = 13)
29
25
23
11
6
10
2
14
23
20
3
0
9
0
11
5
3
10
5
8
4
5
0
0
19
28
9
7
9
9
7
7
6
4
2
much more frequent in those patients who
had their placebo sequence after their
HR sequence, suggesting strongly the
persistence of a beneficial effect from the
HR treatment into the subsequent placebo
period. This 'carry-over' effect was probably
due to the fact that the original protocol did
not foresee a wash-out period between the
two sequences, since this would have further
prolonged the total trial duration.
We therefore undertook a further analysis
of the data, restricted to those patients who
only received HR after an initial placebo
period and, as in the first analysis, among
those patients in whom symptoms persisted
after the 'run-in' period. Although this
somewhat reduced the number of patients
involved, it gave a much clearer picture
of a possible drug effect. The results are
shown in Table IV, which shows that the
'performance' for each symptom under HR
was always superior to that under placebo.
Statistical analysis of these data was not
possible because of the small numbers for
each symptom individually and since the
total of all symptoms is based on different
numbers of patients for each symptom.
Audiometry
The initial values of air conduction or bone
conduction between the two different groups
of patients were never significantly different
(Tables V and VI). During the first sequence
of treatment, with no possible interference
from 'carry-over1 effects, it was very striking
that there was always a significant improve-
ment in hearing for all five frequencies under
HR treatment, but never under placebo,
resulting in significant differences between
the two groups of patients for all five
frequencies. This was true for both air and
bone conduction (with the exception of bone
conduction/500 Hz., where the difference
TABLE IV
SYMPTOMS: ONLY THOSE PATIENTS IN WHOM SYMPTOMS PERSISTED AFTER PLACEBO RUN-IN AND WHO RECEIVED
HR IN THE SECOND SEQUENCE
Vertigo (n = 13)
Nausea (n = 8)
Vomiting (n = 4)
Tinnitus (n = 19)
Deafness (n = 20)
Fullness in ear (n = 11)
Headache (n = 6)
All symptoms together
HR sequence superior
to placebo sequence
8
3
2
7
3
5
3
31
Two sequences
equal
2
5
2
10
17
6
2
44
Placebo sequence superior
to HR sequence
3
0
0
2
0
0
1
6
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TABLE V
EVOLUTION OF AUDIOMETRY FINDINGS (N = NUMBER OF EARS) (FIRST SEQUENCE: 41 EARS (TWO EARS WITHOUT
READINGS); SECOND SEQUENCE 42 EARS (ONE EAR WITHOUT READINGS)
Air conduction; Mean+SEM; Student'( test
Initial
values First sequence Second sequence
250 Hz.
500 Hz.
1,000 Hz.
2,000 Hz.
3,000 Hz.
46.75+3.54
42.86±3.30
46.75+3.70
45.24±2.64
46.75+3.08
40.95+2.86 —
46.25+3.03
39.52±3.O5
44.25+3.17
39.05±3.53
-10.5 +4.24 p<0.05 -2.62+3.73
NS
1
NS
NS
T
NS
•
NS
HR(n = 20)
+5.0 ±4.78
PL(n = 21)
-11.25±4.09
HR
+2.86+4.49
PL
-14.0 +4.03
HR
+6.19+3.58
PL
-10.0 +2.62
HR
+0.71+2.47
PL
-6.75±2.09
HR
+3.10±2.06
NS
p<0.02
NS
p<0.01
NS
p<0.002
NS
p<0.01
NS
T
p<0.02
p<0.05
•
p<0.001
p<0.01
•
p<0.002
PL(n = 21)
-2.86±2.73
HR(n = 21)
-3.81+3.57
PL
-4.05±2.03
HR
-O.71±3.57
PL
-5.48+1.86
HR
— 1.19+2.36
PL
+3.10+2.20
HR
-1.67+1.93
PL
+2.14±2.06
f
NS
NS 1
NS
NS
NS
(p~0.06)
NS
T
NS
1
NS
NS
NS |
NS
Js
NS |
PL HR
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TABLE VI
EVOLUTION OF AUDIOMETRY FINDINGS (n = NUMBER OF EARS) FIRST SEQUENCE: 41 EARS (TWO EARS WITHOUT
READINGS); SECOND SEQUENCE: 42 EARS (ONE EAR WITHOUT READINGS)
Bone conduction; Mean±SEM; Student 'f test
Initial
values First sequence Second sequence
250 Hz.
500 Hz.
1,000 Hz.
2,000 Hz.
3,000 Hz.
35.75±3.76
31.32+3.48
36.0±4.16
37.37±3.18
39.5O±3.8O
35.26±3.83
39.75±3.37
33.42+3.61
41.25+3.40
33.42+3.86
-9.0±3.30 p<0.02 -1.67+3.30 NS
t
NS
1
t
NS
NS
NS
1
HR(n = 20)
+3.16±4.40
PL(n= 19)
-9.25±3.65
HR
+0.26+4.48
PL
-12.25+3.85
HR
+4.47+3.99
PL
-7.0 ±2.47
HR
+3.42+2.71
PL
-6.75+2.18
HR
+2.89+2.07
NS
p<0.02
NS
p<0.01
NS
p<0.02
NS
p<0.01
NS
p<0.05
t
NS(p~0.10)
t
p<0.01
\
p<0.01
p<0.01
PL (21)
-5.79±2.89
HR(19)
-0.48+3.63
PL
-3.42±2.45
HR
+0.48±3.89
PL
-5.26+2.37
HR
0.0 ±3.01
PL
+1.32+1.75
HR
-O.95±1.97
PL
+3.68±2.29
NS
NS 1
(p~0.06)
NS
T
NS
NS |
NS
NS
p<0.05
NS
NS
NS \
NS
4
NS j
PL HR
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between the two groups became not quite
significant, p^O.Ol).
The results in the second sequence
reflected a similar evolution as found with
the symptoms. A further improvement was
seen under HR treatment for two frequencies
for air conduction (1,000 Hz.: p<0.01;
500 Hz.: p~0.06) and for bone conduction
(1,000 Hz.: p<0.05; 250 Hz.: p^0.06). In
the placebo group, whereas a deterioration of
hearing had been seen at all frequencies in
the first sequence, the patients showed a
small (never significant) improvement in the
second sequence. This again suggested a
'carry-over' effect in these patients following
the initial HR treatment for three months.
This resulted in a disappearance of signifi-
cant differences between the two groups at
the end of the trial.
Caloric tests
The results of caloric tests showed already
significant variations between the two tests
performed at the beginning and end of the
placebo run-in period. No clear trend was
seen during the further duration of the trial.
Tolerability
Tolerability of HR was excellent there
was an even distribution of very minor side-
effects in the two treatment periods (eight in
the HR periods and nine in the placebo
periods). None of these appeared to be
clearly drug-related.
Discussion
A very striking placebo effect in the major
symptoms of Meniere's disease confirms the
observations of Thomsen et al. (1979). The
great majority of patients found an improve-
ment in vertigo, nausea and vomiting during
the placebo run-in period. A smaller
percentage even showed a reduction of
tinnitus, deafness, and 'fullness in the ear1.
Since some of the patients then remained
totally free of some symptoms (with the
exception of deafness) during the remaining
six months of the trial, it was necessary to
exclude them from the analysis of results for
that particular symptom.
A further complicating feature of this
study was the appearance of a clear
persistence of improvement, beginning
during the initial HR sequence, into the
second placebo sequence. This was true both
for the symptoms and for the audiometric
findings.
Taking this into consideration, there was a
strong suggestion of a more marked improve-
ment of symptoms during the three-month
period of HR treatment in those patients who
received HR after the placebo period. The
most striking finding was the very clear and
statistically significant improvement in
hearing under treatment with H R This was
true for both air conduction and bone
conduction and for all five frequencies
studied.
The mechanism of this effect is not very
clear but it may have been related to a
reduction of secretion of endolymph or to an
improvement in irrigation of the inner ear.
Tolerance of the drug was excellent, as has
been found in the many other published
studies of this drug in peripheral vascular
disease (Bergquist and Hallbook, 1981).
Abstract
A double-blind, placebo-controlled,
cross-over trial was undertaken in 39
patients with well-defined Meniere's
disease. After a one-month placebo run-in
period, the patients were assigned, on a
randomized basis, to three months'
treatment with O-(B-hydroxyethyl)-
rutosides (HR) (2 g./day) followed by three
months on placebo, or vice-versa.
In spite of a very pronounced placebo
effect and a marked tendency to a 'carry-
over' effect from the first sequence with
HR into the second placebo sequence, there
appeared to be a clear trend to a greater
symptomatic improvement with HR
treatment than with placebo.
The audiometric findings showed a very
clear, uniform superiority under HR treat-
ment, for both air and bone conduction and at
all five frequencies studied(250,500,1,000,
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2,000 and 5,000 Hz.) (p values between Tolerance to HR treatment was excellent,
0.002 and 0.05). Indeed, whereas there was the incidence of side-effects being similar to
a worsening of hearing-loss at each that in the placebo periods.
frequency under placebo during the first
sequence, this was significantly diminished
at each frequency under HR treatment Acknowledgements
There were no significant changes in We wish to express our thanks to Dr.
vestibulometry (caloric test) which showed G. N. Menon, Amsterdam, for his help in
wide variations already during the run-in designing this trial; and to Dr. C. Limoni,
period. Nyon, for the statistical analysis.
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